Want to see ABCL full AI Analyst Report?
Partnered Program Starts
Tracks new collaborations initiated, signaling growth in business development and potential expansion of the company's influence in the biotech sector.AbCellera's partnered program starts have shown a general upward trend, peaking in late 2023. However, the latest earnings call reveals a strategic shift with reduced new discovery partnerships, aligning with their transition to a clinical stage biotech. This pivot is underscored by advancing key programs and a significant partnership with AbbVie, despite facing revenue declines and high R&D expenses. The focus on clinical trials and leveraging their TCE platform suggests a long-term growth strategy, but investors should be cautious of near-term financial pressures.
Date | Partnered Program Starts |
|---|---|
Dec 31, 2023 | 87.00 |
Sep 30, 2023 | 110.00 |
Jun 30, 2023 | 106.00 |
Mar 31, 2023 | 101.00 |
Dec 31, 2022 | 75.00 |
Sep 30, 2022 | 92.00 |
Jun 30, 2022 | 88.00 |
Mar 31, 2022 | 84.00 |
Dec 31, 2021 | 78.00 |
Sep 30, 2021 | 69.00 |